Home > Insider Trading > Filing (0001104659-20-080559)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1722271	Akouos Inc.	AKUS	Pharmaceutical Preparations (2834)	V8

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1114448	Ag Novartis	Forum 1-1.32, Lichtstrasse 35 Basel V8 CH-4056		No	No	No	Yes
1297709	Ltd Bioventures Novartis	Forum 1-1.32, Lichtstrasse 35 Basel V8 CH-4056		No	No	No	Yes

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-06-30	856,262	$0.00	856,262	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-06-30	199,996	$0.00	1,056,258	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-06-30	125,000	$17.00	1,181,258	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2020-06-30	856,262	$0.00	856,262	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-06-30	199,996	$0.00	199,996	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

On June 30, 2020, the Series A Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
Novartis Bioventures Ltd. is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities.
On June 30, 2020, the Series B Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.